Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium

Trabert, Britton; Ness, Roberta B.; Lo-Ciganic, Wei Hsuan; Murphy, Megan; Goode, Ellen L.; Poole, Elizabeth M.; Brinton, Louise A.; Webb, Penelope M.; Nagle, Christina M.; Jordan, Susan J.; Risch, Harvey A.; Rossing, Mary Anne; Doherty, Jennifer A.; Goodman, Marc T.; Lurie, Galina; Kjær, Susanne K.; Høgdall, Estrid; Jensen, Allan; Cramer, Daniel W.; Terry, Kathryn L.; Vitonis, Allison F.; Bandera, Elisa V.; Olson, Sara H.; King, Melony; Chandran, Urmila; Anton‐Culver, Hoda; Ziogas, Argyrios; Menon, Usha; Gayther, Simon A.; Ramus, Susan J.; Gentry-Maharaj, A; Wu, Anna H.; Pearce, Celeste Leigh; Pike, Malcolm C.; Berchuck, Andrew; Schildkraut, Joellen M.; Wentzensen, Nicolas

doi:10.1093/jnci/djt431

Cited by 205 publications

(194 citation statements)

References 58 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…The data for ovarian cancer also suggest a possible inverse association between use of NSAIDs and risk of invasive ovarian cancer although the results of case-control and cohort studies are not consistent. A large pooled analysis of case-control data reported a significant inverse association between use of aspirin and risk of ovarian cancer and a similar, but nonsignificant, association for non-aspirin NSAIDs [70]. By contrast, a meta-analysis of six cohort studies found a future science group www.futuremedicine.com borderline significant association for non-aspirin NSAIDs but no association with aspirin, although a nonsignificant inverse association was again seen for case-control studies [71].…”

Section: • • Nsaidsmentioning

confidence: 98%

Environmental (nongenetic) factors in gynecological cancers: update and future perspectives

Webb

2015

Future Oncol.

View full text Add to dashboard Cite

Globally, gynecological cancers comprise three of the seven most common female cancers and are responsible for more than 1,000,000 new cases and 500,000 deaths annually. This review summarizes current knowledge regarding the role of environmental factors in gynecological cancer etiology and survival, focusing on those that are potentially amenable to intervention. Strong associations with use of exogenous hormones are countered by opposing risks of breast cancer, thus current hormonal preparations are not an option for prevention. Weight control would reduce risk of endometrial cancer but this and other lifestyle modifications are unlikely to have a major effect on gynecological cancer mortality rates. There is little information regarding the potential for lifestyle changes to improve outcomes for women with gynecological cancer.

show abstract

Section: • • Nsaidsmentioning

confidence: 98%

Environmental (nongenetic) factors in gynecological cancers: update and future perspectives

Webb

2015

Future Oncol.

View full text Add to dashboard Cite

show abstract

“…With respect to talc powder, results from case control and prospective studies have been variable; one study showed a modest increase in the risk of ovarian cancer, but other studies have shown no increase in risk with talc use (50,51). Aspirin use was associated with a reduced risk of developing ovarian cancer, especially among women who took daily, low-dose aspirin, regardless of their age; the same associations were not shown for acetaminophen (56 Finally, data from the Nurse's Health Study show that persistent depression -defined as meeting the definition of depression based on current and past questionnaires -might increase the risk of ovarian cancer compared with women who do not exhibit depressive symptoms (48) [H1]Mechanisms/pathophysiology…”

Section: [H2] Risk Factorsmentioning

confidence: 99%

Ovarian cancer

Matulonis

Sood

Fallowfield

et al. 2016

Nat Rev Dis Primers

937

787

View full text Add to dashboard Cite

Ovarian cancer is not a single disease and can be subdivided into at least five different 2 histological subtypes that have different identifiable risk factors, cells of origin, molecular compositions, clinical features and treatments. Ovarian cancer is a global problem, is typically diagnosed at late stage, and has no effective screening strategy. Standard treatments for newly diagnosed cancer consist of cytoreductive surgery and platinum-based chemotherapy. In recurrent cancer, chemotherapy, anti-angiogenic agents, and poly (ADP ribose) polymerase (PARP) inhibitors are used and immunological therapies are currently being tested. High-grade serous carcinoma (HGSC) is the most commonly diagnosed form of ovarian cancer and is typically very responsive to platinum-based chemotherapy at diagnosis. However, in addition to the other histologies, HGSCs frequently relapse and become increasingly resistant to chemotherapy.Consequently, understanding the mechanisms underlying platinum resistance and finding ways to overcome them are active areas of study in ovarian cancer. Significant progress has been made in identifying genes associated with high risk of ovarian cancer (such as BRCA1 and BRCA2) as well as a precursor lesion of HGSC called a serous tubal intraepithelial carcinoma, which hold promise for identifying individuals at high risk of developing the disease and for developing prevention strategies. Competing interestsU.A.M. has served as a consultant for AstraZeneca, ImmunoGen, Pfizer, Genentech, and Merck.

show abstract

“…Ovarian cancer has been linked to several events and conditions which are related to inflammation and repair, including incessant ovulation, endometriosis, exposure to talc and asbestos, and in some studies pelvic inflammatory disease. [Reviewed in [2]] In addition, reduced risks found for aspirin use [3] could be related to direct anti-inflammatory actions, while reduced risks related to tubal ligation and hysterectomy could reflect limited exposure to environmental causes of inflammation. [2] Understanding the role of inflammation in ovarian cancer etiology is complicated by growing recognition that there are least two main types of these tumors, which differ clinically and biologically.…”

Section: Introductionmentioning

confidence: 99%

Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial

Trabert

Pinto

Hartge

et al. 2014

Gynecologic Oncology

View full text Add to dashboard Cite

Objective Pro-inflammatory mechanisms may explain the increased ovarian cancer risk linked to more lifetime ovulations, endometriosis, and exposure to talc and asbestos, as well as decreased risk with non-steroidal antiinflammatory drugs. Limited data are available to estimate ovarian cancer risk associated with levels of circulating inflammatory markers. Methods We conducted a nested case-control study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Pre-diagnostic serum levels of 46 inflammation-related biomarkers (11 with a priori hypotheses; 35 agnostic) were measured in 149 incident ovarian cancer cases and 149 matched controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression and adjusted for identified covariates. Results Increased ovarian cancer risk was associated with elevated levels of C-reactive protein (CRP) [tertile (T)3 vs. T1: OR (95% CI) 2.04 (1.06-3.93), p-trend=0.03], interleukin (IL)-1α [detectable vs. undetectable: 2.23 (1.14-4.34)] and tumor necrosis factor alpha (TNF-α) [T3 vs. T1: 2.21 (1.06-4.63), p-trend=0.04] Elevated IL-8 was non-significantly associated with risk [T3 vs. T1: 1.86 (0.96-3.61), p-trend=0.05] In analyses restricted to serous ovarian cancer (n=83), the associations with CRP and IL-8 remained or strengthened [CRP T3 vs. T1: 3.96 (1.14-11.14), p-trend=0.008; IL-8 T3 vs. T1: 3.05 (1.09-8.51), p-trend=0.03]. Elevated levels of CRP and TNF-α remained positively associated with ovarian cancer risk in analysis restricted to specimens collected at least 5 years before diagnosis (n=56). Conclusion These results suggest that CRP, IL-1α, IL-8, and TNF-α are associated with increased risk of subsequently developing ovarian cancer.

show abstract

Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium

Cited by 205 publications

References 58 publications

Environmental (nongenetic) factors in gynecological cancers: update and future perspectives

Environmental (nongenetic) factors in gynecological cancers: update and future perspectives

Ovarian cancer

Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial

Contact Info

Product

Resources

About